Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
Ho et al., 2015 - Google Patents
[go: Go Back, main page]

Ho et al., 2015 - Google Patents

The immunomodulatory and therapeutic effects of mesenchymal stromal cells for acute lung injury and sepsis

Ho et al., 2015

Document ID
8009876810348265382
Author
Ho M
Mei S
Stewart D
Publication year
Publication venue
Journal of cellular physiology

External Links

Snippet

It is increasingly recognized that immunomodulation represents an important mechanism underlying the benefits of many stem cell therapies, rather than the classical paradigm of transdifferentiation and cell replacement. In the former paradigm, the beneficial effects of cell …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Ho et al. The immunomodulatory and therapeutic effects of mesenchymal stromal cells for acute lung injury and sepsis
Wu et al. Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Monsel et al. Cell-based therapy for acute organ injury: preclinical evidence and on-going clinical trials using mesenchymal stem cells
Laroye et al. Concise review: mesenchymal stromal/stem cells: a new treatment for sepsis and septic shock?
Keane et al. Stem cell–based therapies for sepsis
Castro-Manrreza et al. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications
Radmanesh et al. The immunomodulatory effects of mesenchymal stromal cell‐based therapy in human and animal models of systemic lupus erythematosus
Xu et al. Mesenchymal stem cells in acute lung injury: are they ready for translational medicine?
Cribbs et al. Stem cells in sepsis and acute lung injury
Florez‐Sampedro et al. The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung
Xu et al. Current status of cell-based therapies for COVID-19: evidence from mesenchymal stromal cells in sepsis and ARDS
Zhu et al. Adult stem cells for acute lung injury: remaining questions and concerns
Simovic Markovic et al. Pharmacological inhibition of Gal‐3 in mesenchymal stem cells enhances their capacity to promote alternative activation of macrophages in dextran sulphate sodium‐induced colitis
Cai et al. Mesenchymal stem cells and their exocytotic vesicles
EP2294183A2 (en) Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
Wu et al. Enhanced alleviation of aGVHD by TGF‐β1‐modified mesenchymal stem cells in mice through shifting MΦ into M2 phenotype and promoting the differentiation of Treg cells
Saleh et al. Application of Wharton jelly-derived mesenchymal stem cells in patients with pulmonary fibrosis
Byrnes et al. Mesenchymal stem/stromal cells therapy for sepsis and acute respiratory distress syndrome
Chang et al. Conditioned mesenchymal stem cells attenuate progression of chronic kidney disease through inhibition of epithelial‐to‐mesenchymal transition and immune modulation
da Silva et al. Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?
van Zuylen et al. Post-myocardial infarct inflammation and the potential role of cell therapy
Femminò et al. Extracellular vesicles in cardiac repair and regeneration: Beyond stem-cell-based approaches
Asgharzade et al. A review on stem cell therapy for neuropathic pain
Masterson et al. Mesenchymal stromal cell therapies: potential and pitfalls for ARDS
Li et al. “Remodeling the intestinal immune microenvironment”: immune regulation and tissue regeneration by mesenchymal stem/stromal cells in the repair microenvironment of inflammatory bowel disease